5 January 2016
LivaNova PLC (the “Company” or “LivaNova”) announces on 31 December 2015, Demetrio Mauro, who was until 31 December 2015, a PDMR of LivaNova, received 3,066 ordinary shares of £1.00 each in the capital of the Company (“Ordinary Shares”) in connection with the vesting of his Sorin LTI Awards.
As a result of the above transaction, Demetrio Mauro currently holds 18,759 Ordinary Shares, representing 0.03 percent of the Company’s issued share capital. This announcement is made pursuant to the Disclosure and Transparency Rule 3.1.4R.
LivaNova also informs its shareholders that, on 31 December 2015, it filed a Current Report on Form 8-K (“Form 8-K”) with the U.S. Securities and Exchange Commission (the “SEC”). The Form 8-K can be found on the SEC’s website at www.sec.gov.
A copy of the Form 8-K has been submitted to the National Storage Mechanism on the date of this announcement and is, or will be, available for inspection at http://www.morningstar.co.uk/uk/NSM.
LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.
For more information, please visit www.livanova.com, or contact:
Chief Financial Officer
Investor Relations and Media:
- End -